S U M M A R Y Oxidant burden has been suggested to be a contributor to the pathogenesis of idiopathic pulmonary fibrosis (IPF). The study focused on peroxiredoxin (Prx) II, an antioxidant that has been associated with platelet-derived growth factor (PDGF) signaling and consequent cell proliferation. Localization and expression of Prx II, PDGF receptors (PDGFRa, PDGFRb), Ki67, and nitrotyrosine were assessed in control (n510) and IPF/usual interstitial pneumonia (UIP) (n510) lung biopsies by immunohistochemistry and morphometry. Prx II oxidation was determined by standard and non-reducing Western blots, two-dimensional gel electrophoresis, and mass spectrometry. Prx II localized in the IPF/UIP epithelium and alveolar macrophages. Prx II-positive area in the fibroblastic foci (FF) was smaller than in other parenchymal areas (p50.03) or in the hyperplastic epithelium (p50.01). There was no major Prx II oxidation in IPF/UIP compared with the normal lung. The FF showed only minor immunoreactivity to the PDGFRs; Ki67, a marker of cell proliferation; and nitrotyrosine, a marker of oxidative/nitrosative stress. The results suggest that Prx II oxidation does not relate to the pathogenesis of IPF/UIP and that Prx II, PDGFRs, and proliferating cells colocalize in the IPF/ UIP lung. Unexpectedly, FF represented areas of low cell proliferation. (J Histochem Cytochem 56:951-959, 2008) 
IDIOPATHIC PULMONARY FIBROSIS (IPF) is a fibrotic lung disease with poor prognosis and unknown etiology (American Thoracic Society/European Respiratory Society 2002). A characteristic feature in this disease is the occurrence of fibroblastic foci (FF), i.e., patchy focal areas of fibroblasts (American Thoracic Society/ European Respiratory Society 2002). Progression of the disease and survival of the patients correlate with the numbers of FF lesions in the lung (Nicholson et al. 2002; Tiitto et al. 2006 ). However, the pathogenesis of IPF is still poorly understood.
Several studies indicate that the pathogenesis of IPF is associated with redox imbalance in the lung (Cantin et al. 1989; Kharitonov and Barnes 2001; Lakari et al. 2002; Cho et al. 2004; Hunninghake 2005; Kinnula et al. 2005) . Furthermore, the antioxidant N-acetylcysteine (NAC) is the only drug thus far that has shown any positive effect on the deterioration of the lung function values in patients with IPF (Demedts et al. 2005) . Reactive oxygen species (ROS) contribute to the regulation of growth factor, such as transforming growth factor-b (TGF-b) and platelet-derived growth factor (PDGF) activation or function (Koli et al. 2008) . ROS activate TGF-b, PDGF, and their receptors, and conversely, PDGF and TGF-b promote ROS generation (Sundaresan et al. 1995; Gonzalez-Rubio et al. 1996; Bae et al. 2000; Koli et al. 2008) . IPF is also characterized by the parenchymal accumulation of alveolar macrophages, which release increased amounts of PDGF, mainly of PDGF-B but also PDGF-A (Nagaoka et al. 1990 ). PDGF activity is regulated by the relative expression of its receptors PDGFRa and PDGFRb on the surface of myofibro-blasts. These receptors are induced during fibrogenesis in association with the expansion of the myofibroblast population and production of extracellular matrix (ECM) proteins (Bonner 2004 ). In addition, PDGFRa is induced by a variety of factors such as pollutants, asbestos fibers, and ROS (Gonzalez-Rubio et al. 1996; Bonner et al. 1998; Lasky et al. 1998; Bonner 2007) . In this context, PDGFRa has been suggested to play a central role in the pathogenesis of lung fibrosis (Lasky et al. 1998) .
Peroxiredoxins (Prxs) are involved in redox signaling, antioxidant defense, cell proliferation, and apoptosis (Rhee et al. 2005) . Oxidative stress, e.g., hydrogen peroxide (H 2 O 2 ), causes oxidation at the Prx cysteines and subsequent formation of cysteine sulfenic acid (Cys-SOH). Under severe oxidative stress, Prxs can be further oxidized to sulfinic acid (Cys-SOOH), which results in final Prx inactivation. All six Prxs (Prx I-Prx VI) have been detected in human lung, with a cellspecific expression (Kinnula et al. 2002a ). Furthermore, Prx II functions as a negative regulator of PDGF signaling resulting in an enhanced H 2 O 2 production and PDGFR activation on Prx II deficiency (Choi et al. 2005) . Prx II plays also a role in cell proliferation because loss of Prx II caused neointimal thickening of smooth muscle cells on endothelial injury in mice (Choi et al. 2005) . Similar fibrotic responses to epithelial injury can occur in human IPF.
In this study, the expression levels of all six Prxs were studied to verify if they were altered in the fibrotic lung. Based on the oxidant burden in pulmonary fibrosis (Hunninghake 2005; Kinnula et al. 2005 ) and the role of Prx II in PDGF signaling (Choi et al. 2005) , the study focused further on Prx II localization and expression. Because ROS can inactivate Prxs by oxidation and hyperoxidation (Lehtonen et al. 2005; Rhee et al. 2005) , Prx II oxidation was analyzed by nonreducing Western blot, an antibody detecting hyperoxidized Prx II, two-dimensional gel electrophoresis (2-DE), and mass spectrometry (MS). Because Prx II can cause the suppression of PDGFR activation (Choi et al. 2005) , the expression of PDGFRs and cellular proliferation was further studied.
Materials and Methods
Patients Tissue samples were collected by lung surgery from patients treated at the Helsinki University Central Hospital. The control samples were obtained from normal areas of local lung tumors or hamartomas. The fibrotic tissue was obtained from lung transplantations or thoracoscopic biopsies from patients with IPF/usual interstitial pneumonia (UIP). The Ethics Committee of the Helsinki University Central Hospital approved the study, and the use of the clinical material is regis-tered at www.hus.fi/clinicaltrials. All patients received written information and gave their permission to use the samples.
Peroxiredoxins

IHC.
Four-mm-thick paraffin-embedded tissue sections (control, n510; IPF/UIP, n510; Table 1 ) were deparaffinized in xylene and rehydrated in graded alcohol. Antigens were retrieved by heating the sections in citrate buffer (pH 6.0). Endogenous peroxidase activity was neutralized with 0.3% H 2 O 2. For immunostaining, the Histostain-Plus Kit (Zymed Laboratories; San Francisco, CA) was used according to the manufacturer's instructions. The primary antibodies used were rabbit anti-Prx I-VI (LabFrontier; Seoul, Korea). Detection was performed with 3-amino-9 ethyl-carbazole (AEC) chromogen substrate solution for horseradish peroxidase (Zymed). The sections were counterstained with Mayer's hematoxylin and mounted on glass slides. Control sections were treated with PBS or rabbit primary antibody isotype control (Zymed) to determine the specificity of the staining.
Prx antibodies have shown to be specific and sensitive in detecting these proteins both by Western blotting and immunohistochemistry (IHC) in human lung (Kinnula et al. 2002a,b) .
Morphometry. Digital morphometry of the stained tissue sections was conducted as previously described (Myllärniemi et al. 2008) . Three representative images from the lung parenchyma of each stained section were taken with an Olympus U-CMAD3 camera (Olympus Corporation; Tokyo, Japan) and QuickPHOTO CAMERA 2.1 software (Promicra; Prague, Czech Republic). The areas of positive and negative staining were assessed with Image-Pro Plus 6.1. software (Media Cybernetics; Silver Spring, MD).
Western blot. Tissue biopsies (control, n54; IPF/UIP, n54; Table 2 ) were homogenized in PBS, and 50 mg of protein was used in standard reducing or non- Positive Prx immunoreactivity is seen mainly in the alveolar epithelium (E) and alveolar macrophages and lung parenchyma (P), but not at fibroblastic foci areas (FF). 1O@M (partial)]. Detailed analysis of cysteine oxidation within the detected peptides was done with Peptide-Mass (http://au.expasy.org/tools/peptide-mass.html).
PDGFR
Detection of PDGFR expression in the lung tissue sections from control subjects (n510) and IPF/UIP patients (n510) ( Table 1) was performed by IHC, as described above. The primary antibodies used were a 1:100 dilution of rabbit anti-PDGFRa (Cell Signaling Technology; Danvers, MA) and a 1:100 dilution of rabbit anti-PDGFRb (Cell Signaling Technology). Control sections were treated with PBS or rabbit primary antibody isotype control (Zymed) to determine the specificity of the staining.
Cell Proliferation and Oxidative/Nitrosative Stress Cell proliferation in lung tissue sections (control, n510; IPF/UIP, n510; Table 1 ) was assessed by IHC, as described above. Detection of the proliferation marker Ki67 was performed with a 1:100 dilution of rabbit anti-Ki67 (Thermo Scientific; Fremont, CA). Nitrotyrosine was used as a marker for oxidative/nitrosative stress in the IPF/UIP lungs because it reflects both superoxide (through myeloperoxidase) and nitric oxide-mediated reactions in the cells (Davis et al. 2001) . Nitrotyrosine expression in lung tissue sections (control, n510; IPF/UIP, n510) was assessed by IHC, as described above. Detection of nitrotyrosine was performed with a rabbit anti-nitrotyrosine antibody (Upstate; Lake Placid, NY). Control sections were treated with PBS or rabbit primary antibody isotype control (Zymed) to determine the specificity of the staining.
Statistical Analyses
Data were analyzed using SPSS 12.0.1 for Windows (SPSS; Chicago, IL). Intergroup differences were analyzed with the non-parametric Mann-Whitney U test; p,0.05 was considered statistically significant.
Results
Prx Expression in Normal and IPF/UIP Lung
Prxs are expressed in the bronchial and alveolar epithelium as well as in alveolar macrophages (Kinnula et al. 2002a) . To verify if their localization in lung tissueespecially in the FF lesions-is affected in IPF, all six Prxs were analyzed by IHC. Generally, a similar localization of Prxs was observed in IPF/UIP and healthy control lungs. However, very low, if any, expression of Prxs could be detected in the FF (Figure 1) . Control slides were treated with PBS or appropriate rabbit primary antibody isotype control instead of the primary antibody to determine the specificity of the staining. Both IPF/UIP and healthy lung control slides showed only blue hematoxylin staining, indicating that the red staining achieved with the primary antibodies was specific and restrained to the antigens in question (Prx I-VI, PDGFRa, PDGFRb, Ki67, or nitrotyrosine). Because Prx II plays a special role in the redox balance and in PDGF signaling (Choi et al. 2005 ), this study focused on Prx II. Prx II expression was negative or very weak in the FF of the IPF/UIP lungs (Figures 1  and 2) . By morphometry, the Prx II-positive area in FF was lower than in the other parenchymal areas in IPF/ UIP (p 5 0.03) and lower than in the hyperplastic epithelium of IPF/UIP (p50.01; Figure 2) . The comparison of the Prx II immunoreactivity in normal and IPF/ UIP lung tissue by Western blot showed decreased Prx II protein levels in the diseased lungs (p50.04; Figure 3A ).
Evaluation of Prx II Oxidation in Normal and Fibrotic Lung
Oxidation (i.e., shift from the dimeric form to monomers) of Prx II was studied by non-reducing Western blot ( Figure 3B ). Analysis of the non-reducing Western blot bands showed some Prx II oxidation and monomer formation both in control and IPF/UIP lungs with clear variability, as has already been shown in vitro and in control and chronic obstructive pulmonary disease (COPD) lungs (Lehtonen et al. 2005 (Lehtonen et al. ,2008 . When the protein levels of the monomeric oxidized Prx II in control and IPF/UIP lungs were compared, the band intensities were lower in the IPF/UIP than in the control lung (p50.02 control vs IPF/UIP, Mann-Whitney test; Figure 3B ). Furthermore, the sum intensity of the dimeric and monomeric Prx II forms was significantly lower in IPF/UIP than in the control lung (p50.02). Because the hyperoxidized forms are not necessarily monomers, possible Prx II hyperoxidation was further studied by Western blot with sulfinic acid-specific antibody ( Figure 3C ). It showed a trend toward a decrease in the level of the hyperoxidized Prx II in the IPF lungs. This result is in concordance with the overall decrease of Prx II levels in the IPF/UIP lungs.
Because cysteine oxidation of Prxs causes a change in protein charge reflected by a spot shift within the 2-DE gel Wagner et al. 2002; Chevallet et al. 2003) , the oxidation stage of Prx II in vivo was further evaluated by 2-DE of control (n54) and IPF/UIP lungs (n54; Figure 4 ). In agreement with the Western blot analyses, a slight decrease in the Prx II level was observed in IPF/UIP lungs. However, no shift of the Prx II spot was observed in 2-DE gels of the control and IPF/UIP specimens, indicating no de- tectable difference in the oxidation status. Because the spot matched to the non-oxidized form of an earlier study (Wagner et al. 2002) , this indicates the presence of non-oxidized Prx II. MS analyses confirmed with a spot-specific peptide (3058.5422) that cysteine at position 51 was not oxidized. These data indicate that the majority of Prx II in the control and IPF/UIP lungs is not irreversibly oxidized.
Associations Between Prx II, PRGFR, Proliferation, and Oxidative/Nitrosative Stress The expression of the PDGF receptor and the proliferation marker Ki67 was studied by IHC in the different compartments of the IPF/UIP lungs (the FF, remaining parenchymal tissue, and the epithelium overlying the FF, which are easily identifiable morphologically). By morphometry, PDGFRa-and PDGFRb-positive areas were found in the IPF/UIP epithelium and the lung parenchyma outside the FF, whereas low PDGFR-positive areas were seen in the FF (Figure 5) . Similarly, Ki67positive cells were localized predominantly in the parenchyma and epithelium, outside the FF (Figure 5 ).
Prx II deficiency has been associated with oxidative stress, at least in vitro (Choi et al. 2005) , but whether this phenomenon occurs in vivo is unclear. Local oxidative/nitrosative stress was evaluated by positive immunoreactivity to nitrotyrosine in the control and IPF/UIP lung. These results showed nitrotyrosinepositive cells in the epithelium and inflammatory cells but again the FF in the IPF/UIP lung showed only weak positivity or remained negative. The nitrotyrosinepositive area in the control lung localized to the epithelium ( Figure 5 ).
Discussion
The regulation of intracellular H 2 O 2 levels has been shown to be associated with Prx II. Prx II-deficient fibroblasts exhibit twice as much H 2 O 2 , enhanced activation of PDGFR, and enhanced proliferation. This study showed that the levels of Prx II are very low in the FF of the fibrotic lung, whereas Prx II expression can be seen at the lung parenchyma outside the FF. Prx II expression colocalized with the other Prx proteins, the PDGFRs, nitrotyrosine, and the proliferation marker Ki67. Peroxidase reactions of Prxs can cause the thiol group (-SH) of cysteine residues to be oxidized to sulfenic acid (-SOH). This is highly unstable and quickly forms either a disulfide bridge (-S-S-) with another thiol or is converted to sulfinic acid (-SOOH) or even sulfonic acid (-SOOOH). However, even the overoxidized forms of Prxs can reverse back to the reduced forms (Rhee et al. 2005 ). There are very few studies on Prx oxidation in human material. In our previous study on COPD specimens, no major Prx oxidation could be detected by non-reducing Western blot or 2-DE/MS (Lehtonen et al. 2008) . The results of this study are very similar (i.e., no major differences could be detected between the control and diseased lung by non-reducing Western blot, by an anti-Prx II antibody directed toward the sulfinic acid form of the molecule, or by 2-DE/MS). Individual Cys molecules of Prx II did not differ between the control and diseased lung. Moreover, unpublished data showed no thioredoxin oxidation by 2-DE/ MS in the IPF/UIP samples. In contrast, oxidation of Prxs has been documented in lung cells that have been exposed to H 2 O 2 in vitro (Lehtonen et al. 2005) . These studies have shown that the oxidation of Prxs is generally transient, which may explain the unchanged findings in the lung specimens and also the high resistance of the Prx system against oxidative stress in vivo.
An important question still remaining to be answered is the association between low antioxidant levels and oxidative stress in the FF lesions, and whether there is any major oxidant burden in the FF. Several studies have shown that, besides low Prx II expression, many other antioxidant enzymes are very low or absent in the FF, whereas they are elevated, especially in the hyperplastic epithelium of the IPF/UIP lungs (Lakari et al. 1998; Tiitto et al. 2003; Peltoniemi et al. 2004; Tiitto et al. 2004; Kinnula et al. 2006) . The same is true with the expression of inducible nitric oxide synthase (iNOS), which is intensively expressed in the inflammatory areas and alveolar epithelium but weak or absent in the FF of IPF/UIP lungs (Lakari et al. 2002; Kinnula and Myllarniemi 2008) . Antioxidant enzymes are activated because of oxidative stress and activation of oxidant-producing enzymes, such as iNOS. The results suggest that, in the IPF/UIP lungs, this activation does not occur in the FF but rather in the inflammatory and alveolar epithelial cells, which is the main site of the injury. In contrast, oxidant/antioxidant imbalance in the FF lesions may contribute to the activation of growth factors and their receptors and thus increase cell proliferation. This study could not confirm this phenomenon to occur with Prx II. Despite the very low Prx II levels in FF, no marked cell proliferation could be seen in these lesions. This finding is in full agreement with the fact that oxidant burden was very low in the FF. High antioxidant defense system and oxidative metabolism are generally associated with actively proliferating cells that have high metabolic activity and uncontrolled expansion (Kinnula and Crapo 2004) . This study showed that the high amount of oxidantrelated metabolism is located predominantly outside the FF, colocalizing with proliferating cells in vivo. Nitrotyrosine immunoreactivity in the epithelium of control lung may be caused by changes in the oxidative conditions during anesthesia and surgery as the lung biopsies were obtained.
In conclusion, we showed a colocalization of Prx II immunoreactivity, PDGFR immunoreactivity, oxidant burden, as shown by nitrotyrosine immunoreactivity, and proliferating cells in the IPF/UIP lung. A prominent feature was the low level of Prx II, nitrotyrosine, and Ki67, as a marker of cell proliferation, in the fibroblastic foci in IPF/UIP. The absence of evidence for Prx II oxidation suggests the high resistance of this enzyme against oxidative modifications in vivo.
